DAPAGLIFLOZIN 10mg. IP + VILDAGLIPTIN 100mg. IP

A potent antihyperglycemic agent that treats type II diabetes mellitus patients with inadequate glycemic control. Significantly reduces hyperglycemia with a low risk of hypoglycemia in T2DM patients with inadequate glycemic control. (K Kaku, 2013) Enhances pancreatic islet α- and β-cell responsiveness to glucose, ameliorates insulin secretion, and reduces inappropriate glucagon production. (Degrande, 2008) Exhibits a blood glucose-lowering effect by inhibiting glucose reabsorption at the proximal tubule of the nephron, resulting in decreased renal glucose reabsorption and increased renal glucose excretion. (Pongpan Tanajak, 2018) Improves glucose metabolism by improving islet function. (B Ahrén, 2008) A suitable treatment for type 2 diabetes that benefits patients by increasing treatment adherence and provides effective glycemic control. (Ameya Joshi, 2022) Displays a significant reduction in body weight and pill burden with better glycemic control. (Ameya Joshi, 2022) Ameliorates glycemic control, with more significant reductions in HbA1c, fasting plasma glucose, and postprandial plasma glucose, as well as a higher rate of HbA1c goal achievement. (Ameya Joshi, 2022) An attractive option that demonstrates cardioprotective and renoprotective properties and effectively controls blood sugar levels. (Ameya Joshi, 2022)